On the public citation graph
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
0 signed · 78 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-xopenalex-snapshot
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells
inferredcites →https://doi.org/10.1002/1097-0045(20000901)44:4<271::aid-pros2>3.0.co;2-gopenalex-snapshot
Analysis of type T1 and T2 cytokines in patients with prostate cancer
inferredcites →https://doi.org/10.1002/jcph.906openalex-snapshot
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range
inferredcites →https://doi.org/10.1007/s00280-010-1283-3openalex-snapshot
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
inferredcites →https://doi.org/10.1007/s00280-011-1721-xopenalex-snapshot
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
inferredcites →https://doi.org/10.1007/s00401-016-1545-1openalex-snapshot
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
inferredcites →https://doi.org/10.1007/s11060-010-0143-7openalex-snapshot
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma
inferredcites →https://doi.org/10.1007/s11060-015-1894-yopenalex-snapshot
A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas
inferredcites →https://doi.org/10.1007/s11060-016-2156-3openalex-snapshot
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas
inferredcites →https://doi.org/10.1007/s11060-016-2234-6openalex-snapshot
Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma
inferredcites →https://doi.org/10.1016/0168-8510(91)90141-jopenalex-snapshot
EuroQol©: health-related quality of life measurement. Valuations of health states by the general public in Norway
inferredcites →https://doi.org/10.1016/0168-8510(96)00822-6openalex-snapshot
EuroQol: the current state of play
inferredcites →https://doi.org/10.1016/0169-5002(96)85851-xopenalex-snapshot
Human non-small cell lung cancer cells express a type 2 cytokine pattern
inferredcites →https://doi.org/10.1016/j.ccell.2017.06.003openalex-snapshot
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
inferredcites →https://doi.org/10.1016/j.ccr.2006.02.019openalex-snapshot
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
inferredcites →https://doi.org/10.1016/j.ccr.2009.12.020openalex-snapshot
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
inferredcites →https://doi.org/10.1016/j.cell.2019.06.024openalex-snapshot
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
inferredcites →https://doi.org/10.1016/j.ijrobp.2008.08.050openalex-snapshot
Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies
inferredcites →https://doi.org/10.1016/j.ijrobp.2018.01.001openalex-snapshot
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
inferredcites →https://doi.org/10.1016/j.jneuroim.2013.08.013openalex-snapshot
Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level
inferredcites →https://doi.org/10.1016/s1470-2045(06)70665-9openalex-snapshot
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
inferredcites →https://doi.org/10.1038/cddis.2012.153openalex-snapshot
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression
inferredcites →https://doi.org/10.1038/mt.2012.278openalex-snapshot
Optimizing Glioblastoma Temozolomide Chemotherapy Employing Lentiviral-based Anti-MGMT shRNA Technology
inferredcites →https://doi.org/10.1038/nri.2017.52openalex-snapshot
The non-canonical NF-κB pathway in immunity and inflammation
inferredcites →https://doi.org/10.1038/s41416-019-0551-1openalex-snapshot
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
inferredcites →https://doi.org/10.1038/sj.gene.6364135openalex-snapshot
IL-10 stimulatory effects on human NK cells explored by gene profile analysis
inferredcites →https://doi.org/10.1056/nejmoa043330openalex-snapshot
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
inferredcites →https://doi.org/10.1056/nejmoa043331openalex-snapshot
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
inferredcites →https://doi.org/10.1056/nejmoa1308345openalex-snapshot
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
inferredcites →https://doi.org/10.1056/nejmoa1308573openalex-snapshot
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
inferredcites →https://doi.org/10.1073/pnas.94.9.4348openalex-snapshot
Cytoplasmic sequestration of an O 6 -methylguanine-DNA methyltransferase enhancer binding protein in DNA repair-deficient human cells
inferredcites →https://doi.org/10.1074/jbc.m005447200openalex-snapshot
Regulation of the HumanO 6-Methylguanine-DNA Methyltransferase Gene by Transcriptional Coactivators cAMP Response Element-binding Protein-binding Protein and p300
inferredcites →https://doi.org/10.1093/annonc/mdt522openalex-snapshot
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)
inferredcites →https://doi.org/10.1093/neuonc/nox029openalex-snapshot
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
inferredcites →https://doi.org/10.1097/coc.0000000000000239openalex-snapshot
CTLA-4 and PD-1 Pathways
inferredcites →https://doi.org/10.1155/2012/831090openalex-snapshot
Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy
inferredcites →https://doi.org/10.1158/0008-5472.can-06-3820openalex-snapshot
Novel Mechanism whereby Nuclear Factor κB Mediates DNA Damage Repair through Regulation of O 6-Methylguanine-DNA-Methyltransferase
inferredcites →https://doi.org/10.1158/0008-5472.can-16-1162openalex-snapshot
Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-3002openalex-snapshot
The Definition of Primary and Secondary Glioblastoma
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0801openalex-snapshot
STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
inferredcites →https://doi.org/10.1200/jco.2002.09.084openalex-snapshot
Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma
inferredcites →https://doi.org/10.1200/jco.2005.06.502openalex-snapshot
Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
inferredcites →https://doi.org/10.1200/jco.2006.06.6290openalex-snapshot
Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium Trial
inferredcites →https://doi.org/10.1200/jco.2009.21.9832openalex-snapshot
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
inferredcites →https://doi.org/10.1200/jco.2009.23.6497openalex-snapshot
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
inferredcites →https://doi.org/10.1200/jco.2009.26.3541openalex-snapshot
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
inferredcites →https://doi.org/10.3171/2011.1.jns101657openalex-snapshot
Quality of life in patients with intracranial gliomas: the impact of modern image-guided surgery
inferredcites →https://doi.org/10.3171/2011.2.jns10998openalex-snapshot
An extent of resection threshold for newly diagnosed glioblastomas
inferredcites →https://doi.org/10.3390/cancers11070996openalex-snapshot
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival
inferredcites →https://doi.org/10.4049/jimmunol.1103826openalex-snapshot
Immune Mechanism of the Antitumor Effects Generated by Bortezomib
inferredcites →https://doi.org/10.4049/jimmunol.161.5.2099openalex-snapshot
Constitutive IL-10 Production Accounts for the High NK Sensitivity, Low MHC Class I Expression, and Poor Transporter Associated with Antigen Processing (TAP)-1/2 Function in the Prototype NK Target YAC-1
inferredcites →https://doi.org/10.4049/jimmunol.165.5.2783openalex-snapshot
Proinflammatory Effects of IL-10 During Human Endotoxemia
inferredcites →https://doi.org/10.4049/jimmunol.176.8.4757openalex-snapshot
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4888426openalex-extracted
Investigative Radiogenomic Analysis of Gliomas by Combining miRNA Profiles and Functional MRI
inferred← citeshttps://doi.org/10.1007/s11010-022-04584-0openalex-snapshot
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
inferred← citeshttps://doi.org/10.1007/s43440-025-00739-0openalex-snapshot
Marizomib in the therapy of brain tumors—how far did we go and where do we stand?
inferred← citeshttps://doi.org/10.1016/b978-0-443-27356-8.00016-4openalex-snapshot
Targeting cell cycle proteins in brain cancer
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102228openalex-snapshot
Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review
inferred← citeshttps://doi.org/10.1021/acsanm.3c02122openalex-snapshot
Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells
inferred← citeshttps://doi.org/10.1038/s41698-026-01552-5openalex-snapshot
Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors
inferred← citeshttps://doi.org/10.1080/17425247.2022.2124967openalex-snapshot
Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance
inferred← citeshttps://doi.org/10.1093/noajnl/vdad037openalex-snapshot
Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI
inferred← citeshttps://doi.org/10.1186/s41687-022-00499-yopenalex-snapshot
Characteristics of health-related quality of life and related factors in patients with brain tumors treated with rehabilitation therapy
inferred← citeshttps://doi.org/10.23736/s0390-5616.22.05718-6openalex-snapshot
Ulipristal-temozolomide-hydroxyurea combination for glioblastoma: in-vitro studies
inferred← citeshttps://doi.org/10.23736/s1973-9087.25.08573-9openalex-snapshot
Improved health-related quality of life after rehabilitation in patients with brain tumors is not affected by tumor type
inferred← citeshttps://doi.org/10.3389/fcell.2022.1022191openalex-snapshot
Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway
inferred← citeshttps://doi.org/10.3389/fimmu.2023.894853openalex-snapshot
Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 T-cell infiltration in glioblastoma
inferred← citeshttps://doi.org/10.3389/fneur.2024.1369625openalex-snapshot
Translation and validation of the Neurological Assessment in Neuro-Oncology scale to Brazilian Portuguese
inferred← citeshttps://doi.org/10.3390/cancers14153769openalex-snapshot
Refining the Role of Pyruvate Dehydrogenase Kinases in Glioblastoma Development
inferred← citeshttps://doi.org/10.3390/cancers16213635openalex-snapshot
Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma
inferred← citeshttps://doi.org/10.3390/cells10061411openalex-snapshot
Friend or Foe: Paradoxical Roles of Autophagy in Gliomagenesis
inferred← citeshttps://doi.org/10.3390/curroncol30110702openalex-snapshot
Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine
inferred← citeshttps://doi.org/10.3390/ijms22158289openalex-snapshot
Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy
inferred← citeshttps://doi.org/10.3390/ijms24031879openalex-snapshot
Pro- vs. Anti-Inflammatory Features of Monocyte Subsets in Glioma Patients
inferred← citeshttps://doi.org/10.3390/membranes12090823openalex-snapshot
Interaction of Bortezomib with Cell Membranes Regulates Its Toxicity and Resistance to Therapy
inferred← citeshttps://doi.org/10.3892/ol.2022.13632openalex-snapshot
Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)
inferred← citeshttps://doi.org/10.7324/japs.2021.110417openalex-snapshot
Cytotoxicity screening of cotreatment with temozolomide and azithromycin on human glioblastoma cells U87
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.